OakChart

Dogwood Therapeutics Inc

DWTXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:58 PM ET

1.18-0.05 (-4.07%)
2026-11-12 00:31 CET
Market cap
47.02 USD m
Revenue, TTM
0.10 USD m
Net income, TTM
-25.18 USD m
Free cash flow, TTM
-16.47 USD m
EPS diluted, TTM
-0.89
P/E
-
Compare

Price

DWTX against its 20, 50 and 200-day averages
2050200missearnings
1.002.003.004.00256K512KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DWTXclose 1.1820-day 1.1750-day 1.45200-day 1.901.1852w low

83.2% under the 52-week high of 7.04 on 12 Dec 2025. 52-week low 0.90 on 3 Nov 2026. Last 15 sessions, 53.2% high to low

Volume 0.91× normal · the line is the 50-bar volume average

Profile

DWTX
52-week range, 5% of the way up
0.907.04

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Employees8
IPODec 17, 2020
Beta2.12
ATR, 14d0.15
Rel volume0.91
Short float1.13%
Insider own74.09%
Inst own10.03%

Snapshot

6 groups

Valuation

Index-
Market Cap45.11M
Enterprise Value40.28M
Income-25.18M
Sales0.10M
Book/sh1.88
Cash/sh0.13
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPODec 17, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S451.09
P/B0.63
P/C9.11
P/FCF-
EV/EBITDA-
EV/Sales402.79
Quick Ratio2.78
Current Ratio2.78
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.89
EPS next Y-0.71
EPS next Q-0.15
EPS this Y87.87%
EPS next Y17.92%
EPS next 5Y52.79%
EPS past 3/5Y36.34% 25.53%
Sales past 3/5Y- -
EPS Y/Y TTM96.43%
Sales Y/Y TTM-
EPS Q/Q98.26%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.9.68% -

Ownership

Insider Own74.09%
Insider Trans0.00%
Inst Own10.03%
Inst Trans1.08%
ROA-30.05%
ROE-35.58%
ROIC-39.23%
Gross Margin-54.70%
Oper. Margin-18672.57%
Profit Margin-25179.61%
SMA200.51%
SMA50-18.82%
SMA200-38.04%
Trades-

Technical

Shs Outstand34.13M
Shs Float9.91M
Short Float1.13%
Short Ratio1.34
Short Interest0.11M
52W High7.04 -83.25%
52W Low0.90 30.97%
Volatility17.10% 12.22%
ATR (14)0.15
RSI (14)44.69
Beta2.12
Rel Volume0.91
Avg Volume83.27K
Volume75,715

Performance

Perf Week14.56%
Perf Month-9.23%
Perf Quarter-40.40%
Perf Half Y-36.56%
Perf YTD-71.63%
Perf Year-79.08%
Perf 3Y-93.91%
Perf 5Y-99.16%
Perf 10Y-
Recom1.00
Target Price13.50
Prev Close1.23
Price1.18
Change %-4.07%

Peers

Mkt cap
TickerCompanyMkt cap
LXRXLexicon Pharmaceuticals Inc832.59M
VRTXVertex Pharmaceuticals Inc138.69B
HRTXHeron Therapeutics Inc68.36M
TNXPTonix Pharmaceuticals Holding Corp75.20M
ENSCEnsysce Biosciences Inc7.00M
SCLXScilex Holding Company11.40M
EPRXEupraxia Pharmaceuticals Inc541.95M
CNTBConnect Biopharma Holdings Ltd43.38M
AXSMAxsome Therapeutics Inc7.85B
PCRXPacira BioSciences Inc1.46B

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • Dogwood Therapeutics Announces Third Quarter 2026 Financial Results (GlobeNewswire)
  • Dogwood Announces $5 Million Private Placement with CK Life Sciences Int'l., (Holdings) Inc. (GlobeNewswire)
  • Dogwood to Participate in the 2026 Maxim Growth Summit (GlobeNewswire)
  • Dogwood Announces Completion of Enrollment in Ongoing Halneuron Phase 2b Trial (GlobeNewswire)
  • Dogwood to Host Virtual KOL Event to Discuss Halneuron for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 (GlobeNewswire)
  • Dogwood Therapeutics Announces Second Quarter 2026 Financial Results (GlobeNewswire)
  • Dogwood Enrolls First 200 Patients in Ongoing Halneuron Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026 (GlobeNewswire)
  • Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board (GlobeNewswire) -9.55%
  • Dogwood Therapeutics Announces Commencement of Halneuron Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study (GlobeNewswire) -7.10%
  • Dogwood Therapeutics Announces First Quarter 2026 Financial Results (GlobeNewswire) +6.45%
  • Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 (GlobeNewswire) -5.45%
  • Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M (GlobeNewswire) -8.50%
  • Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy (GlobeNewswire)
  • Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) -7.76%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.140-0.155-0.1600.100.002
2026Q22026-08-13-0.340-0.140-0.3380.000.002
2026Q12026-05-14-0.150-0.193-0.1490.000.003
2025Q42026-03-18-0.260-0.860-0.2600.000.003
2025Q32025-11-06-8.200-1.160-8.2030.000.003
2025Q22025-08-13-1.990-0.790-1.9920.000.002
2025Q12025-05-08-8.450-2.090-8.4500.000.002
2024Q42025-03-14-6.290-1.415-6.2890.000.002
2024Q32024-11-07-2.050-1.177-2.0540.000.003
2024Q22024-08-08-1.250-1.583-1.1460.000.003
2024Q12024-05-09-0.070-0.040-1.6760.000.001
2023Q42024-02-29-0.060-0.070-1.4320.000.001
2023Q32023-11-13-0.060-0.090-1.6170.000.001
2023Q22023-08-10-0.080-0.050-1.9570.000.001
2023Q12023-05-11-0.080-0.200-2.0690.000.00-
2022Q42023-03-14-0.110-0.150-2.7890.000.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-2.100--31.1450.00-
2021FY-1.920-2.050-47.9040.000.00
2022FY-1.110-1.170-27.6600.000.00
2023FY-7.000-7.250-7.0510.000.00
2024FY-12.520-6.030-12.5160.00-
2025FY-7.130-6.620-7.1300.000.00
2026FY--0.865--0.10
2027FY--0.710--0.00
2028FY--0.750--9.42
2029FY--0.200--57.40
2030FY-0.630--69.67

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-051000.000.000.00
2026Q4S2026-08-131000.000.000.00
2026Q4S2026-07-011000.000.000.00
2026Q4S2026-05-142000.000.000.00
2026Q4S2026-03-232000.000.000.00
2026Q4S2026-03-181000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00
2026Q4S2025-11-081000.000.000.00
2026Q4S2025-11-071000.000.000.00
2026Q4S2025-11-061000.000.000.00
2026Q4S2025-11-051000.000.000.00
2026Q4R2026-11-05100-0.16-0.16-0.16

Estimate history

EPS, annual-6.38-7.467-31.145-47.904-27.66-7.051-12.516-7.135-0.8899
Period20182019202020212022202320242025TTM
EPS, quarterly-2.054-6.289-8.45-1.992-8.203-0.26-0.149-0.338-0.143
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000000.1
Period20182019202020212022202320242025TTM
Sales, quarterly000000000.1
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.3310.3310.3320.3330.7330.7331.33229.74434.13
Period20182019202020212022202320242025MRQ
Shares, quarterly1.111.3321.9111.9112.29329.74433.40233.6334.13
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.100.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.150.070.010.000.000.000.000.000.00
Gross Profit-0.05-0.07-0.010.000.000.000.000.000.00
Selling, General and Administrative Excl. Other18.6227.9012.225.4512.3215.6410.012.181.96
Research and Development11.6121.873.531.738.0710.800.190.840.85
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-18.67-27.97-12.23-5.45-12.32-15.64-10.01-2.18-1.96
Interest Expense--0.090.000.000.000.380.300.15
Unusual Expense9.196.130.000.000.000.000.000.000.00
Net Income Before Taxes-27.63-34.04-12.35-5.30-12.25-15.96-10.35-2.47-2.11
Income Taxes-2.450.22-0.000.000.000.000.000.000.00
Consolidated Net Income-25.18-34.26-12.35-5.30-12.25-15.96-10.35-2.47-2.11
Net Income From Continuing Operations-25.18-34.26-12.35-5.30-12.25-15.96-10.35-2.47-2.11
Net Income-25.18-35.51-12.86-5.30-12.25-15.96-10.35-2.47-2.11
EPS (Recurring)-0.55-6.27-12.52-7.05-27.66-47.90-31.14-7.47-6.38
EPS (Basic, Before Extraordinaries)-0.89-7.13-12.52-7.05-27.66-47.90-31.14-7.47-6.38
EPS (Diluted)-0.89-7.13-12.52-7.05-27.66-47.90-31.14-7.47-6.38
EBITDA-18.61-27.90-12.22-5.45-12.32-15.64-10.01-2.18-1.96
Non-Operating Income (Expense)0.240.07-0.030.150.07-0.320.040.001E-05
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.350.280.380.620.580.327.43--
Price To Sales Ratio460.75--------
Gross Margin-54.70--------
Operating Margin-18,672.57--------
Net Margin-25,179.61--------
Shares Outstanding34.1329.741.330.730.730.330.330.330.33
Market Capitalization47.0247.023.3211.074.3342.6162.3767.50-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.100.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.100.020.020.020.020.020.020.01
Gross Profit-0.00-0.02-0.02-0.02-0.02-0.02-0.02-0.01
Selling, General and Administrative Excl. Other4.914.865.063.7915.793.914.417.53
Research and Development3.353.252.672.3414.522.572.442.32
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.92-4.87-5.08-3.81-15.81-3.92-4.43-7.54
Interest Expense------0.150.16
Unusual Expense0.009.190.000.000.000.006.130.00
Net Income Before Taxes-4.88-14.01-4.99-3.75-15.75-3.81-10.73-7.73
Income Taxes-0.00-2.480.000.03-0.000.000.19-0.00
Consolidated Net Income-4.88-11.53-4.99-3.78-15.74-3.81-10.92-7.73
Net Income From Continuing Operations-4.88-11.53-4.99-3.78-15.74-3.81-10.92-7.73
Net Income-4.88-11.53-4.99-3.78-15.74-3.81-12.18-8.24
EPS (Recurring)-0.14-0.15-0.15-0.26-8.20-1.99-5.47-6.29
EPS (Basic, Before Extraordinaries)-0.14-0.34-0.15-0.26-8.20-1.99-8.45-6.29
EPS (Diluted)-0.14-0.34-0.15-0.26-8.20-1.99-8.45-6.29
EBITDA-4.90-4.86-5.06-3.79-15.79-3.91-4.41-7.53
Non-Operating Income (Expense)0.030.050.090.060.060.12-0.020.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.440.430.360.120.040.050.070.17
Price To Sales Ratio460.75-------
Gross Margin-4.61-------
Operating Margin-4,917.30-------
Net Margin-4,882.94-------
Shares Outstanding34.1333.6333.4029.742.291.911.911.33
Market Capitalization47.0254.1470.48123.6714.729.129.573.32

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments6.5214.853.327.0314.0129.800.310.03
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets1.911.700.851.341.771.680.010.01
Total Current Assets8.4316.544.178.3715.7831.470.320.04
Net Property, Plant & Equipment0.180.220.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.00
Long-Term Note Receivable-0.02------
Intangible Assets81.3977.520.000.000.000.000.000.00
Deferred Tax Assets0.496.90------
Other Assets0.180.000.000.000.000.000.000.02
Total Assets90.66101.214.178.3715.7831.470.320.07
Short Term Debt Incl. Current Port. of LT Debt0.060.050.000.000.000.000.000.00
Accounts Payable0.000.000.000.000.000.370.040.15
Other Current Liabilities3.003.130.361.041.281.161.591.18
Total Current Liabilities3.063.180.361.041.281.531.621.33
Long Term Debt0.1189.940.000.000.000.003.640.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities12.5918.22------
Other Liabilities0.000.000.000.000.000.000.000.00
Total Liabilities15.76111.340.361.041.281.535.261.33
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity74.90-10.123.817.3314.5029.94-17.62-15.15
Total Shareholders Equity74.90-10.123.817.3314.5029.94-17.62-15.15
Accumulated Minority Interest0.000.000.000.000.000.0012.6813.88
Total Equity74.90-10.123.817.3314.5029.94-4.94-1.26
Total Liabilities & Stockholders Equity90.66101.214.178.3715.7831.470.320.07
Book Value Per Share2.52-7.605.199.9943.5290.13-53.18-45.71
Tangible Book Value Per Share-0.22-65.795.199.9943.5290.13-53.18-45.71
Full-Time Employees8124453--
Price to Book Ratio0.650.882.330.472.942.08-3.14-
Return on Assets-35.71-23.44-84.50-101.45-67.56-65.09-1,295.65-
Return on Equity-105.78--95.14-112.22-71.83-167.93--
Return on Invested Capital-45.67-15.47-139.12-167.17-110.06-34.56--
Quick Ratio2.765.2111.628.0212.3720.550.190.03
Current Ratio2.765.2111.628.0212.3720.550.190.03

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-25.18-34.26-12.35-5.30-12.25-15.96-10.35-2.47-2.11
Depreciation0.070.070.01------
Other Funds (Non Cash)10.8618.484.130.620.580.327.430.07-0.02
Funds from Operations-16.70-15.49-8.21-4.68-11.67-15.64-2.92-2.41-2.13
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.23-0.13-0.58-0.190.20-0.05-0.970.320.87
Cash from Operating Activities-16.47-15.62-8.79-4.87-11.47-15.69-3.90-2.09-1.27
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.003.760.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.003.760.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00-0.070.000.00
Change in Capital Stock11.384.3416.701.164.49-0.1031.530.001.22
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock11.384.3416.701.164.49-0.1031.530.001.22
Proceedsfrom Stock Options11.384.3416.701.164.49-0.3031.350.001.22
Issuance or Reduction of Debt, Net0.003.000.000.000.000.001.932.370.00
Change in Long Term Debt0.003.000.000.000.000.001.932.370.00
Issuance of Long Term Debt0.003.000.000.000.000.001.932.370.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.05-0.05-0.000.000.000.000.000.000.00
Other Financing Activities Uses-0.05-0.05-0.000.000.000.000.000.000.00
Cash from Financing Activities11.327.2816.701.164.49-0.1033.382.371.22
Exchange Rate Effect-0.030.01-0.14------
Net Change in Cash-5.18-8.3211.53-3.71-6.98-15.7929.490.28-0.05
Free Cash Flow-16.47-15.62-8.79-4.87-11.47-15.69-3.90-2.09-1.27
Preferred Dividends (Cash Flow)---0.000.000.00-0.070.000.00
Deferred Taxes & Investment Tax Credit-0.22-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments4.959.6113.236.5210.1313.40
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.101.421.781.911.531.30
Total Current Assets6.0411.0315.008.4311.6614.70
Net Property, Plant & Equipment0.130.140.160.180.190.21
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets69.4269.3180.0381.3980.1381.76
Deferred Tax Assets---0.49--
Other Assets0.020.020.020.180.000.00
Total Assets75.6180.5095.2190.6691.9996.69
Short Term Debt Incl. Current Port. of LT Debt0.060.060.060.060.050.05
Accounts Payable0.170.410.000.000.000.00
Other Current Liabilities1.952.362.503.002.541.83
Total Current Liabilities2.172.832.563.062.601.89
Long Term Debt0.060.070.090.110.120.13
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities9.219.2011.9112.5911.8912.13
Other Liabilities0.030.030.030.000.000.00
Total Liabilities11.4712.1314.5815.7614.6114.15
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00110.46100.66
Common Equity64.1368.3780.6274.90-33.07-18.12
Total Shareholders Equity64.1368.3780.6274.9077.3982.54
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity64.1368.3780.6274.9077.3982.54
Total Liabilities & Stockholders Equity75.6180.5095.2190.6691.9996.69
Book Value Per Share1.882.032.412.52-14.42-9.48
Tangible Book Value Per Share-0.15-0.030.02-0.22-49.36-52.26
Full-Time Employees---8--
Price to Book Ratio0.650.670.84-0.29-0.81-0.51
Return on Assets-30.05-40.68-29.47-35.71-81.05-49.32
Return on Equity-35.58-47.77-64.57-105.78-97.54-57.75
Return on Invested Capital-7.61-16.85-6.18-5.04-20.31-4.61
Quick Ratio2.783.895.862.764.497.80
Current Ratio2.783.895.862.764.497.80

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-4.88-11.53-4.99-3.78-15.74-5.06
Depreciation0.020.020.020.020.020.02
Other Funds (Non Cash)0.599.730.490.0512.091.32
Funds from Operations-4.27-4.27-4.47-3.68-3.63-3.73
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.360.66-0.110.040.36-0.30
Cash from Operating Activities-4.64-3.61-4.59-3.64-3.27-4.03
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00---
Change in Capital Stock5E-050.0011.290.090.00-0.12
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5E-050.0011.290.090.00-0.12
Proceedsfrom Stock Options0.000.0011.290.090.00-0.12
Issuance or Reduction of Debt, Net0.000.000.000.000.003.00
Change in Long Term Debt0.000.000.000.000.003.00
Issuance of Long Term Debt0.000.000.000.000.003.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.050.00-3.00
Other Financing Activities Uses0.000.000.00-0.050.000.00
Cash from Financing Activities5E-050.0011.290.030.00-0.12
Exchange Rate Effect-0.03-0.01-0.000.00-0.000.01
Net Change in Cash-4.66-3.626.70-3.60-3.28-4.14
Free Cash Flow-4.64-3.61-4.59-3.64-3.27-4.03

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.13%0.1M9.9M69.99K
2026-10-150.71%0.1M8.8M66.49K
2026-09-300.44%0.0M8.8M70.45K
2026-09-150.84%0.1M8.8M77.61K
2026-08-311.01%0.1M8.8M78.08K
2026-08-140.54%0.0M9.3M72.15K
2026-07-310.85%0.1M8.7M82.00K
2026-07-150.84%0.1M8.7M97.62K
2026-06-301.11%0.1M8.7M101.32K
2026-06-150.31%0.0M8.7M100.43K
2026-05-290.75%0.1M8.7M97.21K
2026-05-151.24%0.1M8.7M94.34K
2026-04-300.38%0.1M33.4M80.97K
2026-04-150.60%0.0M7.7M65.32K
2026-03-310.91%0.1M7.7M57.27K
2026-03-130.65%0.1M7.7M51.35K
2026-02-270.73%0.1M7.7M49.59K
2026-02-130.86%0.1M7.7M49.19K
2026-01-300.20%0.1M32.1M52.27K
2026-01-150.28%0.1M32.1M57.01K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06EFFECTEffectiveness filing by commission orderSEC
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-30S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-27SCHEDULE 13D/ASEC
2026-10-21SCHEDULE 13D/ASEC
2026-10-198-KCurrent report2026-10-19SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-178-KCurrent report2026-06-16SEC
2026-05-15SCHEDULE 13GSEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-04-27ARSAnnual report to security holders. 2025-12-31SEC
2026-04-27DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-16SEC
2026-04-17PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-16SEC
2026-03-268-KCurrent report2026-03-26SEC
2026-03-1810-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-188-KCurrent report2026-03-18SEC
2026-03-128-KCurrent report2026-03-11SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-05SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-05SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-05SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ARMISTICE CAPITAL, LLC9.31%
MILLENNIUM MANAGEMENT LLC1.02%
VANGUARD CAPITAL MANAGEMENT LLC0.39%
GEODE CAPITAL MANAGEMENT, LLC0.27%
VANGUARD FIDUCIARY TRUST CO0.19%
BlackRock, Inc.0.08%
NORTHERN TRUST CORP0.07%
CITADEL ADVISORS LLC0.03%
Tower Research Capital LLC0.01%
UBS Group AG0.01%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.39%
Fidelity Extended Market Index Fund0.17%
Goldman Sachs International Small Cap Insights Fund0.09%
iShares Micro-Cap ETF0.08%
Goldman Sachs International Equity Insights Fund0.06%
Old Westbury Small & Mid Cap Strategies Fund0.04%
Fidelity Series Total Market Index Fund0.04%
Avantis International Equity ETF0.03%
Fidelity Total Market Index Fund0.01%
Fidelity Nasdaq Composite Index Fund0.01%

OakChart. DWTX. Cached 15 minutes.

Some panels did not load: ratings, insider.